Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression date from endothelial cells stimulated with anti-HLA class I and anti-A antibody

ABSTRACT: While donor specific antibody (DSA) against HLA class II could frequently cause chronic antibody-mediated rejection (ABMR) in organ transplantation, anti-A/B antibody would not do so, because blood group ABO-incompatible transplantation has shown favorable graft outcome. Recently, an increasing attention has been paid to the importance of direct allorecognition of CD4 T-cells against HLA-class II expressed on graft endothelial cells. However, the effect of allo-antibody binding on its allorecognition remains unclear. Microarray analysis and molecular profiling demonstrated that CD275 (PD-L1) expression was increased by anti-A/B ligation-mediated ERK inactivation in endothelial cells despite IFNγ stimulation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE120545 | GEO | 2018/09/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Mir profiling of human whole blood samples from kidney transplant recipients from BIOMARGIN consortium

Project description:We investigated blood miRNAs as potential non-invasive biomarkers in kidney transplantation as part of the BIOMARGIN consortium (ClinicalTrials.gov, number NCT02832661). Blood samples were collected at time of the 717 renal allograft biopsies, in four European transplant centers. Profiling of mIR transcriptomes was performed in a multistage discovery-to-validation study. Antibody-mediated rejection (ABMR) is the most common cause of allograft failure after kidney transplantation. The revised Banff 2017 classification defines ABMR as conditions in which histologic evidence of acute and chronic injury is associated with evidence of current/recent antibody interaction with vascular endothelium and serologic evidence of donor-specific antibodies (DSA) to human leukocyte antigen (HLA) or non-HLA antigens

2021-05-31 | E-MTAB-9595 | biostudies-arrayexpress

MicroRNA Regulation in Blood Cells of Renal Transplanted Patients with Interstitial Fibrosis/Tubular Atrophy and Antibody-Mediated Rejection

Project description:We performed small RNA-Seq and compared expression levels of microRNAs of whole blood cells isolated from patients after kidney transplantation with stable graft function (SGF), antibody-mediated rejection (ABMR) and T cell-mediated rejection (TCMR).

2018-08-20 | GSE115816 | GEO

Transcriptomic profiling of circulating T follicular helper cells in kidney transplant recipients

Project description:We compared the transcriptomic profile between patients without donor-specific HLA antibodies (DSA-), patients with donor-specific HLA antibodies without antibody-mediated rejection (DSA+ ABMR-) and patients with donor-specific HLA antibodies and antibody-mediated rejection (DSA+ ABMR+). We found that patient with DSA+ ABMR+ had a distinct transcriptomic profile compared to DSA- and DSA+ ABMR-, characterized by upregulation of genes encoding for germinal center T follicular helper cells function, T-B cell interaction and costimulatory molecules.

2021-07-01 | GSE134477 | GEO

Transcriptomic profiling of circulating T follicular helper cells (cTFH) and activated memory B cells (ABC) in kidney transplant recipients

2020-11-09 | GSE145503 | GEO

Expression date from endothelial cells stimulated with anti-HLA class I and anti-A antibody

Project description:Expression date from endothelial cells stimulated with anti-HLA class I and anti-A antibody

| PRJNA493548 | ENA

RNA-Seq of human micro- and macrovascular endothelial cells

Project description:Background: If the majority of antibody mediated rejections (AMRs) of the renal allograft are due to anti-HLA antibodies, non anti-HLA antibodies have also been suspected. The occurrence of non anti-HLA-associated AMRs remains associated with unresolved diagnostic and therapeutic issues. Methods: To better understand the pathomechanisms of these rejections, we identified, though a nation-wide study, kidney transplant recipients (KTRs), without anti-HLA donor specific antibodies, experiencing acute graft dysfunction within the first 3 months after transplantation and severe microvascular injury on biopsy (called acute microvascular rejections, AMVR).

2019-05-30 | E-MTAB-7003 | biostudies-arrayexpress

Peripheral blood transcriptomic profiles of kidney allograft pathology: biological pathways, comparison with biopsy signals and cellular origin

Project description:To further explore the transcriptional changes in the peripheral blood leukocytes at time of Antibody-mediated rejection (ABMR), scRNAseq analysis was performed on 12 peripheral blood samples (6 ABMR and 6 stable patients paired for age and time after transplantation) using 10X Genomic technology.

2022-03-03 | E-MTAB-11450 | biostudies-arrayexpress

Subthreshold rejection activity in many kidney transplants currently classified as having no rejection.

Project description:Most kidney transplant patients who undergo biopsies are classified as having no rejection based on consensus thresholds. However, we hypothesized that because these patients have normal adaptive immune systems, T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR) may exist as subthreshold activity in some transplants currently classified as no rejection. Subthreshold molecular TCMR and/or ABMR activity molecular activity was detectable as elevated classifier scores in many biopsies classified as no rejection, with ABMR activity in many TCMR biopsies and TCMR activity in many ABMR biopsies. In biopsies classified as no rejection histologically and molecularly, molecular TCMR classifier scores correlated with increases in histologic TCMR features and molecular injury, lower eGFR, and higher risk of graft loss, and molecular ABMR activity correlated with increased glomerulitis and donor-specific antibody. No rejection biopsies with high subthreshold TCMR or ABMR activity had a higher probability of having TCMR or ABMR respectively diagnosed in a future biopsy. We conclude that many kidney transplant recipients have unrecognized subthreshold TCMR or ABMR activity, with significant implications for future problems.

2024-09-04 | GSE275126 | GEO

Gene expression analysis of molecules with known function in HLA class II antigen processing and presentation in hematopoietic and (cytokine pre-treated) non-hematopoietic cells.

Project description:Gene expression analysis of molecules with known function in HLA class II antigen processing and presentation. Various hematopoietic cell types and (cytokine pre-treated) non-hematopoietic cells that are targeted in Graft-versus-Leukemia reactivity and Graft-versus-Host Disease were collected. Expression was compared between the different hematopoietic and non-hematopoietic cell types for the Invariant chain, HLA-DMA, HLA-DMB, HLA-DOA and HLA-DOB genes. The data show that the Invariant chain, HLA-DMA, HLA-DMB and HLA-DOA genes are expressed in all or the majority of cell types with HLA class II surface expression, whereas expression of the HLA-DOB gene is restricted to professional antigen presenting B-cells and mature dendritic cells.

2012-06-19 | GSE38798 | GEO

Successful eculizumab-based desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes

Project description:Background: Plasmapheresis/rituximab-based desensitization therapy has successfully reduced anti-ABO antibody levels and suppressed antibody-mediated rejection (AMR) in ABO-incompatible (ABOi) kidney transplantation (KT). However, high titers of anti-ABO antibodies in some patients are refractory to standard desensitization, leading to loss of KT opportunities or AMR. Methods: Eculizumab-based desensitization was used to rescue high-titer ABOi KT patients refractory to plasmapheresis/rituximab-based desensitization. Results: The initial titers of anti-ABO IgG antibodies in the two patients were 1:512 and >1:1024; the final pre-transplant titers after desensitization were 1:128 and 1:64. Both patients received eculizumab from the day of KT to two or four weeks post-KT and maintained stable renal function up to one-year post-transplantation without overt infectious complications, despite early episodes of suspicious AMR or borderline T cell-mediated rejection. Molecular phenotype analysis of allograft biopsies using the Banff Human Organ Transplant gene panel revealed that gene expression patterns in the ABOi KT with eculizumab group overlapped with those in the ABOi KT with AMR group more than in the ABOi KT without AMR group, except for complement pathway-related gene expression. Anti-ABO antibody titers decreased to low levels 1–3 months post-transplant in the eculizumab group in parallel with decreasing anti-B-specific B cells at this time point. Conclusions: Short-term eculizumab-based desensitization therapy is promising for rescuing ABOi KT recipients with unacceptably high anti-ABO antibody titers refractory to plasmapheresis-based desensitization therapy.

2024-10-15 | GSE274052 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data